MedDataX Logo

A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.

NCT ID: NCT00468975

Last Updated: 2010-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A study to determine the ability of different doses of PF-610,355 to open the airways in asthmatic patients by comparison with placebo and a marketed drug that also opens the airways in asthmatic patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-610,355

Intervention Type DRUG

Salmeterol

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Reversible asthmatic patients (\>15% increase in FEV1 following 200ug salbutamol).
* FEV1 greater than or equal to 60% predicted
* Stable disease for at least the previous 3 months

Exclusion Criteria

* Subjects requiring rescue medication on greater than 2 occasions in the 72 hours prior to screening
* Subjects with a history of pulmonary disease other than asthma.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Berlin, , Germany

Site Status

Pfizer Investigational Site

Großhansdorf, , Germany

Site Status

Pfizer Investigational Site

Wiesbaden, , Germany

Site Status

Pfizer Investigational Site

Gothenburg, , Sweden

Site Status

Pfizer Investigational Site

Lund, , Sweden

Site Status

Pfizer Investigational Site

Manchester, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany Sweden United Kingdom

Related Links

Access external resources that provide additional context or updates about the study.

https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A7881004&StudyName=A%20Blinded%20Study%20To%20Examine%20The%20Ability%20Of%20PF-610%2C355%20To%20Open%20The%20Airways%20In%20Asthmatic%20Patients.

To obtain contact information for a study center near you, click here.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A7881004

Identifier Type: -

Identifier Source: org_study_id